论文部分内容阅读
目的：评价病毒唑雾化吸入治疗由呼吸道合胞病毒（RSV）所致婴幼儿流行性喘憋性肺炎的疗效．方法：将60例流行性喘憋性肺炎儿童随机分为两组，分别给予病毒唑雾化吸入及静脉滴注，用药后逐日记录主要症状体征的改善情况，并于住院当日及第5日检查血气分析二次．结果：病毒唑雾化吸入组在主要症状体征的改善方面及提高PaO2及SaO2方面明显优于对照组．且无副作用．结论：病毒唑雾化吸入治疗由RSV所致婴幼儿流行性喘憋性肺炎是一种安全有效的方法．
Objective: To evaluate the efficacy of ribavirin inhalation in the treatment of epidemic pneumonia in infants and young children caused by respiratory syncytial virus (RSV). Methods: Sixty children with epidemic pneumonia were randomly divided into two groups, treated with inhaled ribavirin and intravenous drip respectively. The improvement of major symptoms and signs were recorded daily after treatment. The children were checked on the day of hospitalization and on the 5th day Blood gas analysis twice. Results: Ribavirin inhalation group was better than the control group in improving the main symptoms and signs and improving PaO2 and SaO2. And no side effects. Conclusion: Ribavirin inhalation is a safe and effective method for the treatment of epidemic pneumonia in infants and young children caused by RSV.